Medley, Inc. (JP:4480)
:4480
Top Page
Medley
(4480)
Select Model
Select Model
Rating:51Neutral
Price Target:
¥1,870.00
▼(-20.09% Downside)
Action:ReiteratedDate:02/18/26
The score is primarily constrained by weak technicals (price below all major moving averages and bearish momentum) and elevated valuation (high P/E with no dividend yield data). Financial performance is mixed: strong revenue growth and positive cash flow are outweighed by sharp 2025 margin compression and increased leverage.
Positive Factors
Multi-year revenue growth
Sustained top-line expansion from ¥6.8B to ¥36.8B over several years indicates durable demand and successful market penetration. Persistent revenue growth supports scale, product investment and diversification, reducing reliance on one-time gains and enabling longer-term strategy execution.
Negative Factors
Sharp net margin compression
A steep decline in net margin over one year signals structural pressure on operating leverage, rising costs, or adverse mix shifts. Lower bottom-line profitability reduces retained earnings and the firm's ability to fund growth internally, making performance more sensitive to revenue volatility.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue growth
Sustained top-line expansion from ¥6.8B to ¥36.8B over several years indicates durable demand and successful market penetration. Persistent revenue growth supports scale, product investment and diversification, reducing reliance on one-time gains and enabling longer-term strategy execution.
Read all positive factors
Medley (4480) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥68.06B
Dividend YieldN/A
Average Volume (3M)504.45K
Price to Earnings (P/E)77.0
Beta (1Y)0.38
Revenue Growth31.95%
EPS Growth-40.95%
CountryJP
Employees1,487
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-4.10
Shares Outstanding32,738,600
10 Day Avg. Volume497,800
30 Day Avg. Volume504,450
Financial Highlights & Ratios
PEG Ratio-1.19
Price to Book (P/B)5.08
Price to Sales (P/S)2.04
P/FCF Ratio22.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)75.56
Revenue Forecast (FY)¥46.09B
Medley Business Overview & Revenue Model
Company Description
Medley, Inc. operates platforms for recruitment and medical businesses in Japan. It operates through three segments: HR Platform Business, Medical Platform Business, and New Services. The company manages JobMedley, a human resource recruitment sys...
How the Company Makes Money
null...
Medley Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
52
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.06B | 36.79B | 29.30B | 20.53B | 14.19B | 10.86B |
| Gross Profit | 20.74B | 23.19B | 18.92B | 13.59B | 9.72B | 6.99B |
| EBITDA | 5.03B | 4.61B | 4.00B | 4.50B | 2.14B | 1.25B |
| Net Income | 1.44B | 975.00M | 2.80B | 2.57B | 1.02B | 563.00M |
Balance Sheet | ||||||
| Total Assets | 47.42B | 41.25B | 45.41B | 25.52B | 22.04B | 20.33B |
| Cash, Cash Equivalents and Short-Term Investments | 13.52B | 8.57B | 19.00B | 15.35B | 14.42B | 14.29B |
| Total Debt | 18.27B | 16.09B | 15.18B | 1.66B | 2.38B | 3.11B |
| Total Liabilities | 29.36B | 26.45B | 25.19B | 7.89B | 6.87B | 6.28B |
| Stockholders Equity | 18.07B | 14.80B | 20.21B | 17.55B | 15.08B | 13.97B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.28B | 2.38B | 3.47B | 1.64B | 796.39M |
| Operating Cash Flow | 0.00 | 3.49B | 2.45B | 3.87B | 2.01B | 1.04B |
| Investing Cash Flow | 0.00 | -7.13B | -10.72B | -1.66B | -751.00M | -3.29B |
| Financing Cash Flow | 0.00 | -6.78B | 11.90B | -1.22B | -927.00M | 2.22B |
Medley Technical Analysis
Neutral
2340.00
Price Trends
2025.58
Positive
2227.16
Negative
2465.92
Negative
Market Momentum
23.63
Negative
59.71
Neutral
86.98
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4480, the sentiment is Neutral. The current price of 2340 is above the 20-day moving average (MA) of 1915.10, above the 50-day MA of 2025.58, and below the 200-day MA of 2465.92, indicating a neutral trend. The MACD of 23.63 indicates Negative momentum. The RSI at 59.71 is Neutral, neither overbought nor oversold. The STOCH value of 86.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4480.
Medley Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥1.09T | 18.91 | 12.15% | 1.01% | 33.50% | 17.26% | |
67 Neutral | ¥10.36B | 38.97 | ― | 5.30% | 0.09% | -48.79% | |
63 Neutral | ¥65.71B | 228.03 | ― | 0.39% | 6.17% | -8918.66% | |
63 Neutral | ¥231.00B | 26.76 | ― | 0.43% | 20.55% | 48.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥68.06B | 77.03 | 5.76% | ― | 31.95% | -40.95% | |
44 Neutral | ¥2.66B | -4.28 | ― | ― | 16.19% | -4.42% |
* Healthcare Sector Average
JP:4480
Medley
2,071.00
-1,204.00
-36.76%
JP:2413
M3
1,564.00
-77.51
-4.72%
JP:3902
Medical Data Vision Co.Ltd.
1,685.00
1,275.00
310.98%
JP:4438
Welby Inc.
320.00
14.00
4.58%
JP:4483
JMDC Inc.
3,590.00
557.75
18.39%
JP:9341
GENOVA Inc.
567.00
-327.11
-36.58%
Medley Corporate Events
Medley Nears ¥3 Billion Share Buyback Cap With Completion of Latest Repurchase
Mar 3, 2026
Medley has completed a share repurchase program authorized by its board in November 2025, buying back 22,100 common shares for ¥41.6 million via market transactions on the Tokyo Stock Exchange between March 1 and 2, 2026. This transaction for...
Medley Nears Completion of ¥3 Billion Share Buyback Program
Mar 2, 2026
Medley, Inc. reported progress on its ongoing share repurchase program authorized by its board in November 2025, detailing that it bought back 840,100 common shares on the Tokyo Stock Exchange between February 1 and February 28, 2026, for a total ...
Medley Moves to Expand Business Scope With Articles of Incorporation Revision
Feb 24, 2026
Medley, Inc. plans to broaden its corporate purposes through amendments to its Articles of Incorporation to support future business expansion and development. The revisions, to be submitted for approval at the March 27, 2026 annual shareholders me...
Medley Maintains Board Lineup and Sets 2026 Management Structure
Feb 13, 2026
Medley has proposed reappointing its existing board, including President and CEO Kohei Takiguchi and CFO Ryo Kawahara, with all internal and independent external directors slated for re-nomination at the upcoming shareholders’ meeting in Mar...
Medley Posts Strong Sales Growth but Profit Slumps, Eyes Rebound in 2026
Feb 13, 2026
Medley reported consolidated net sales of ¥36.79 billion for the fiscal year ended Dec. 31, 2025, up 25.5% year on year, while EBITDA rose 17.2%, but operating profit fell 7.6% and profit attributable to owners of parent dropped 65.1% amid a ...
Medley Reports No Share Buybacks in January Under Ongoing Repurchase Program
Feb 2, 2026
Medley, Inc., listed on the Tokyo Stock Exchange Prime Market, has an authorized share repurchase program for its common stock, allowing buybacks of up to 1.5 million shares, or 4.8% of its outstanding shares excluding treasury stock, for a total ...
Medley Secures ¥5 Billion in Unsecured Loans for Working Capital and Share Buybacks
Jan 22, 2026
Medley, Inc. has resolved at its board meeting to secure a total of ¥5 billion in new financing through unsecured loans from Mizuho Bank and Sumitomo Mitsui Banking Corporation, with a five-year term and equal principal repayment structure. T...
Medley Reports Progress on Ongoing Share Repurchase Program
Jan 5, 2026
Medley, Inc. reported progress on its ongoing share repurchase program, disclosing that it bought back 234,500 common shares for a total of 566.9 million yen via market transactions on the Tokyo Stock Exchange between December 1 and December 31, 2...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.